If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
57
results.
Updated on
20/08/2026 [06:45:00]
Results 50 to 57 of 57
Absstract of: WO2026152242A1
The present invention relates to a polysaccharide with cytotoxic activity against human colon, human lung, human melanoma and murine leukaemia tumour cells, as well as antioxidant and healing activity. The invention also relates to a method for producing the polysaccharide, its uses and applications, particularly via drugs for treating cancer and/or antioxidant and healing compositions. The polysaccharide of the present invention can be produced from biomass, particularly from fungi, and preferably from the fungus Bovistella utriformis.
Absstract of: US20260207710A1
0000 Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering (a) an IL-2 conjugate, and (b) a chimeric antigen receptor (CAR) therapy. Also disclosed herein are methods for treating diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, comprising administering an IL-2 conjugate.
Absstract of: WO2026154051A1
The present invention relates to gliptins, the inhibitors of dipeptidyl peptidase 4, also known as DPP-4 inhibitors, for use in the treatment and/or prevention of diseases in a human subject. The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of gliptins, pharmaceutically acceptable salts thereof and hydrates thereof, for use in a therapeutic or prophylactic method of treating a MALT-1 involving disease in a subject, preferably selected from allergic inflammatory disease, an autoimmune disease, multiple myeloma and glioma, in a human subject in need thereof. The present invention also relates to the use of gliptins as an allosteric MALT1 inhibitor for use in a method of treating a MALT-1 involving disease in a subject, preferably selected from an allergic inflammation disease, multiple sclerosis, multiple myeloma and glioma. The present invention is also directed to the field of personalized cancer care and treatment.
Absstract of: US20260209356A1
0000 The present invention concerns a vector including the cassette coding for B7-H3 CAR gene obtained using the single chains variable fragments (scFv) of the monoclonal IgG antibody NE97, a method for the production thereof and B7-H3 CAR genetically modified effector cells (such as T cells or innate cells such as NK and NK-T cells) for the treatment of CD276 (B7-H3) positive tumors such as lymphoid malignancies, leukemia and solid tumors such as CNS tumors, extra-cranial and intracranial tumors and autoimmune diseases.
Absstract of: US20260207738A1
Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
Absstract of: US20260209308A1
0000 Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×10<5 >to 5.0×10<6 >of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Nº publicación: US20260209298A1 23/07/2026
Applicant:
INDUSTRY UNIV COOPERATION FOUNDATION HANYANG UNIV ERICA CAMPUS [KR]
INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
Absstract of: US20260209298A1
0000 The present invention is to confirm that PLK1 induces tumor formation and cancer metastasis through IGFBP5 phosphorylation, and provide an IGFBP5 mutant in which a region phosphorylated by PLK1 is mutated and a vector expressing same. The IGFBP5 mutant of the present invention maintains a binding ability to PLK1, and thus binds to PLK1 overexpressed competitively with wild-type IGFBP5 in cancer cells, thereby making it possible to inhibit tumor formation and cancer metastasis, and the provision of a vector expressing the mutant in cancer cells can inhibit cancer mobility and invasiveness and inhibit tumor formation. The mutant of the present invention is safe because it does not affect the inherent function of IGFBP5 in normal cells, and thus can be useful in the treatment of various diseases caused by abnormal cell growth, especially degenerative diseases such as primary and metastatic solid cancer and leukemia.
BOPI
Electronic site
